This study explores the cost-effectiveness and potential budgetary consequences of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer (NSCLC) in the context of the US health care system.
https://ift.tt/2BfvMlk
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
http://bit.ly/2SylJiJ
-
Duraisamy Balaguru, Matthew Rodriguez, Stephanie Leon, Louis K Wagner, Charles W Beasley, Andrew Sultzer, Mohammed T Numan Annals of P...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου